BE2014C071I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C071I2 BE2014C071I2 BE2014C071C BE2014C071C BE2014C071I2 BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2 BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004174770 | 2004-06-11 | ||
JP2004327111 | 2004-11-10 | ||
US63059604P | 2004-11-23 | 2004-11-23 | |
US11/150,792 US7378423B2 (en) | 2004-06-11 | 2005-06-10 | Pyrimidine compound and medical use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2014C071I2 true BE2014C071I2 (hu) | 2024-10-08 |
Family
ID=35600249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2014C071C BE2014C071I2 (hu) | 2004-06-11 | 2014-11-28 |
Country Status (2)
Country | Link |
---|---|
US (8) | US7378423B2 (hu) |
BE (1) | BE2014C071I2 (hu) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7312044B2 (en) | 2003-03-07 | 2007-12-25 | The Trustees Of Columbia University In The City Of New York | Type 1 ryanodine receptor-based methods |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
EP1859793B1 (en) * | 2005-02-28 | 2011-04-20 | Eisai R&D Management Co., Ltd. | Novel combinational use of a sulfonamide compound in the treatment of cancer |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
EP2099443A4 (en) * | 2006-11-10 | 2010-05-05 | Syndax Pharmaceuticals Inc | ASSOCIATION OF ERA + LIGANDS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF CANCER |
JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
US20100298270A1 (en) * | 2007-07-23 | 2010-11-25 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
US20100267779A1 (en) * | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
WO2009049018A1 (en) * | 2007-10-10 | 2009-04-16 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
EP2249644A4 (en) * | 2008-02-08 | 2012-05-30 | Poniard Pharmaceuticals Inc | PICOPLATIN AND AMRUBICIN USEFUL IN THE TREATMENT OF LUNG CANCER |
JP2011527703A (ja) * | 2008-07-11 | 2011-11-04 | ノバルティス アーゲー | (a)ホスホイノシタイド3−キナーゼ阻害剤および(b)Ras/Raf/Mek経路のモジュレーターの配合物 |
EP2362775B1 (en) | 2008-11-20 | 2015-08-05 | GlaxoSmithKline LLC | Chemical compounds |
US8647067B2 (en) * | 2008-12-09 | 2014-02-11 | General Electric Company | Banked platform turbine blade |
JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Mek阻害剤に対する耐性を付与するmek突然変異 |
WO2010109468A1 (en) * | 2009-03-26 | 2010-09-30 | Mapi Pharma Hk Limited | Process for the preparation of alogliptin |
EP2480084B1 (en) * | 2009-09-23 | 2014-11-12 | GlaxoSmithKline LLC | Pharmaceutical combination |
CA2775125C (en) | 2009-09-23 | 2019-01-08 | Glaxosmithkline Llc | Combination of a mek inhibitor and an akt inhibitor to treat cancer |
CN102665719A (zh) | 2009-09-28 | 2012-09-12 | 葛兰素史密斯克莱有限责任公司 | 组合 |
HRP20191617T1 (hr) | 2009-10-16 | 2019-12-13 | Novartis Ag | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf |
BR112012011677A8 (pt) * | 2009-11-17 | 2018-06-12 | Glaxosmithkline Llc | Combinação, kit de combinação e uso de uma combinação |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
CA2791247C (en) | 2010-03-09 | 2019-05-14 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
WO2011146712A1 (en) * | 2010-05-21 | 2011-11-24 | Glaxosmithkline Llc | Combination |
US20130165456A1 (en) | 2010-08-26 | 2013-06-27 | Tona M. Gilmer | Combination |
WO2012068339A2 (en) * | 2010-11-17 | 2012-05-24 | Glaxosmithkline Llc | Methods of treating cancer |
US8906879B2 (en) | 2010-12-20 | 2014-12-09 | Glaxosmithkline Intellectual Property (No. 2) Limited | Combination for the treatment of cancer |
TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
CA2846454A1 (en) | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
WO2013136249A1 (en) * | 2012-03-14 | 2013-09-19 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
JP6335169B2 (ja) | 2012-08-17 | 2018-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法 |
BR112015009134A2 (pt) * | 2012-10-25 | 2017-07-04 | Glaxosmithkline Llc | combinação |
IN2015DN04094A (hu) * | 2012-11-30 | 2015-10-09 | Glaxosmithkline Llc | |
JP2016504409A (ja) | 2013-01-09 | 2016-02-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited | 組合せ |
US20150353542A1 (en) | 2013-01-14 | 2015-12-10 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
UY35587A (es) | 2013-05-28 | 2014-12-31 | Glaxosmithkline Ip No 2 Ltd | Método de tratamiento del cáncer |
BR112015028326A8 (pt) | 2013-06-03 | 2018-01-23 | Novartis Ag | combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica |
WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
WO2015059677A1 (en) | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
WO2015087279A1 (en) | 2013-12-12 | 2015-06-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
CN111534580B (zh) | 2013-12-28 | 2024-06-04 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
WO2015105822A1 (en) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Cancer treatment method |
EP2913048A1 (en) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
JP2018526377A (ja) | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | がんを治療するための、任意にpi3k阻害剤のbyl719を更に含む、cdk4/6阻害剤のlee011とmek1/2阻害剤トラメチニブの組み合わせ物 |
EA201891093A1 (ru) | 2015-11-03 | 2018-10-31 | Янссен Байотек, Инк. | Антитела, специфически связывающие pd-1, и их применение |
RU2605400C1 (ru) * | 2015-11-13 | 2016-12-20 | ЗАО "Р-Фарм" | ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2 |
US10861357B2 (en) * | 2015-11-13 | 2020-12-08 | Nike, Inc. | Athletic bib |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
KR101796684B1 (ko) * | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
UY37866A (es) | 2017-09-07 | 2019-03-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
JP2022509534A (ja) * | 2018-10-30 | 2022-01-20 | ニューベイション・バイオ・インコーポレイテッド | Bet阻害剤としてのヘテロ環式化合物 |
EP3886987B1 (en) | 2018-11-30 | 2023-11-15 | GlaxoSmithKline Intellectual Property Development Limited | Compounds useful in hiv therapy |
KR20210107069A (ko) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
EP3920932A4 (en) * | 2019-02-06 | 2022-10-19 | Aurobindo Pharma Limited | METHOD FOR PREPARING AN ACETIC ACID SOLVATE OF TRAMETINIB |
EP3997070A4 (en) | 2019-07-02 | 2023-07-26 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
WO2021018866A1 (en) * | 2019-07-30 | 2021-02-04 | Edvince Ab | Mek inhibitor for treatment of stroke |
CA3149796A1 (en) | 2019-08-02 | 2021-02-11 | Onehealthcompany, Inc. | Anti-cancer agents for the treatment of canine cancers |
US12268692B2 (en) | 2020-04-10 | 2025-04-08 | Postsurgical Therapeutics, Inc. | Combinatorial targeted therapy methods |
WO2021263188A1 (en) * | 2020-06-25 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Live cell engagement assay |
US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
CN114853754B (zh) * | 2022-05-23 | 2023-04-18 | 云白药征武科技(上海)有限公司 | 一种硫代酰胺衍生物及其制备方法和应用 |
AR129423A1 (es) | 2022-05-27 | 2024-08-21 | Viiv Healthcare Co | Compuestos útiles en la terapia contra el hiv |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3139432A (en) | 1963-06-24 | 1964-06-30 | Mead Johnson & Co | Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones |
DE4035479A1 (de) | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
IL143231A0 (en) | 1998-12-15 | 2002-04-21 | Warner Lambert Co | Use of a mek inhibitors for preventing transplant rejection |
HUP0104693A3 (en) | 1998-12-16 | 2003-12-29 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
WO2000040237A1 (en) | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
AU2483000A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Treatment of asthma with mek inhibitors |
TR200200205T2 (tr) | 1999-07-16 | 2002-06-21 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
WO2002006520A1 (fr) | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Methode de criblage de compose regulant la transduction de signaux mek/erk et utilisation medicale dudit compose |
YU2503A (sh) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
JPWO2002087620A1 (ja) | 2001-04-27 | 2004-08-12 | 中外製薬株式会社 | 軟骨形成促進剤 |
NZ518726A (en) | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
MEP46108A (en) | 2002-01-22 | 2011-02-10 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
-
2005
- 2005-06-10 US US11/150,792 patent/US7378423B2/en active Active
-
2008
- 2008-03-21 US US12/053,133 patent/US20080312228A1/en not_active Abandoned
-
2009
- 2009-11-25 US US12/626,443 patent/US8835443B2/en active Active
-
2014
- 2014-08-07 US US14/454,404 patent/US20150183812A1/en not_active Abandoned
- 2014-11-28 BE BE2014C071C patent/BE2014C071I2/fr unknown
-
2016
- 2016-02-24 US US15/052,581 patent/US20170029418A1/en not_active Abandoned
-
2017
- 2017-10-27 US US15/795,973 patent/US20180273531A1/en not_active Abandoned
-
2019
- 2019-05-20 US US16/416,895 patent/US20200109139A1/en not_active Abandoned
-
2021
- 2021-12-08 US US17/545,664 patent/US20220380362A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20220380362A1 (en) | 2022-12-01 |
US20180273531A1 (en) | 2018-09-27 |
US20150183812A1 (en) | 2015-07-02 |
US20170029418A1 (en) | 2017-02-02 |
US20100240613A1 (en) | 2010-09-23 |
US7378423B2 (en) | 2008-05-27 |
US20200109139A1 (en) | 2020-04-09 |
US20060014768A1 (en) | 2006-01-19 |
US8835443B2 (en) | 2014-09-16 |
US20080312228A1 (en) | 2008-12-18 |